<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581214</url>
  </required_header>
  <id_info>
    <org_study_id>201805045</org_study_id>
    <nct_id>NCT03581214</nct_id>
  </id_info>
  <brief_title>Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate</brief_title>
  <acronym>O2P2</acronym>
  <official_title>Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 2/3 of laboring women receive supplemental oxygen (O2) in an attempt to reverse
      perceived fetal hypoxia on electronic fetal monitoring (EFM). O2 supplementation is most
      commonly used in patients with Category II EFM, a class of EFM patterns designed in part to
      identify fetal acidemia. This liberal use of O2 in laboring patients is concerning because
      hyperoxygenation in infants is associated with adverse outcomes including retinopathy and
      abnormal neurodevelopment. Furthermore, excess O2 exposure is linked to free radical
      generation and subsequent oxidative cell damage. This calls for a closer look at the safety
      of intrauterine O2 exposure. The proposed project explores potential mechanisms for harm with
      maternal O2 supplementation in laboring patients with Category II EFM. Specifically, this
      project will determine the effect of O2, compared to room air (RA), on umbilical cord and
      maternal levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), markers of free
      radical-induced oxidative stress. The study will also explore the potential effect of
      peripartum O2 exposure on placental oxidative stress. We will also use magnetic resonance
      imaging to investigate the effect of in utero hyperoxygenation on the neonatal brain.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Umbilical artery malondialdehyde</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Umbilical artery 4-hydroxynonenal</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal malondialdehyde</measure>
    <time_frame>Within 1 hour of delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal 4-hydroxynonenal</measure>
    <time_frame>Within 1 hour of delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placental 4-hydroxynonenal</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal diffusion weighted magnetic resonance imaging of the brain</measure>
    <time_frame>Within 72 hours of delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Intrauterine Resuscitation</condition>
  <arm_group>
    <arm_group_label>Room air</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Room air (no mask)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10L/min Oxygen by facemask</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No oxygen</intervention_name>
    <description>No facemask, room air only</description>
    <arm_group_label>Room air</arm_group_label>
    <other_name>Room air</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>10Liters/minute oxygen by facemask</description>
    <arm_group_label>Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton

          -  Gestational age â‰¥37 weeks

          -  Spontaneous labor or induction of labor

          -  English speaking

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Major fetal anomaly

          -  Multiple gestation

          -  Category III electronic fetal monitoring

          -  Maternal hypoxia

          -  Preeclampsia

          -  Intrauterine growth restriction

          -  Pregestational diabetes

          -  Tobacco use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is in pregnant females only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Nandini Raghuraman</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

